Galmed Pharmaceuticals Ltd expected to post a loss of15cents a share - Earnings Preview
GLMD Stock | USD 2.88 0.17 5.57% |
About 65% of Galmed Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Galmed Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Galmed Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Galmed Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Galmed |
Galmed Pharmaceuticals Ltd is expected to report results on May 9 . Refinitivs mean analyst estimate for Galmed Pharmaceutical...
Read at kalkinemedia.com
Galmed Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Galmed Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Galmed Pharmaceuticals Fundamental Analysis
We analyze Galmed Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galmed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galmed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Galmed Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Galmed Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Galmed Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Galmed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Galmed Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Galmed Pharmaceuticals Related Equities
MBIO | Mustang Bio | 5.26 | ||||
LPTX | Leap Therapeutics | 4.43 | ||||
ADAP | Adaptimmune Therapeutics | 3.23 | ||||
MREO | Mereo BioPharma | 1.58 | ||||
ABEO | Abeona Therapeutics | 1.01 | ||||
ADVM | Adverum Biotechnologies | 0.68 | ||||
KOD | Kodiak Sciences | 1.48 | ||||
PDSB | PDS Biotechnology | 2.28 | ||||
PIRS | Pieris Pharmaceuticals | 2.35 | ||||
FBIO | Fortress Biotech | 2.83 | ||||
ACHL | Achilles Therapeutics | 2.86 | ||||
AFMD | Affimed NV | 2.93 | ||||
AKBA | Akebia Ther | 3.03 | ||||
FBIOP | Fortress Biotech | 3.32 | ||||
APTO | Aptose Biosciences | 5.26 |
Complementary Tools for Galmed Stock analysis
When running Galmed Pharmaceuticals' price analysis, check to measure Galmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galmed Pharmaceuticals is operating at the current time. Most of Galmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Galmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Galmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |